PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. (Q33413496)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

phase II clinical trial

0 references

monoclonal antibody

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Nadia Zaffaroni

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Alfonso Marchianò

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Maria Grazia Daidone

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Roberto Salvioni

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Filippo de Braud

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

P Giannatempo

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

E Farè

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

D Raggi

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

F Crippa

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

M Maffezzini

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

E Togliardi

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

A M Gianni

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

26 February 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Investigational New Drugs

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

32

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

555-560

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24566706%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

https://scigraph.springernature.com/pub.10.1007/s10637-014-0074-9

0 references

Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

Phase II study of sunitinib in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

Phase II study of everolimus in metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

In vitro tumoral progression of human bladder carcinoma: role for TGFbeta

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

Edmonton symptom assessment scale: Italian validation in two palliative care settings.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0074-9

21 January 2018

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers

1 reference

https://pubmed.ncbi.nlm.nih.gov/24566706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24566706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33413496&oldid=1647990007"